Status: Recruiting
Study of IMC-P115C in Advanced PRAME-Positive Cancers
Phase 1 First-in-human study of the safety and efficacy of IMC-P115C as a single agent and in combination with standard of care (SOC) agents in participants with advanced PRAME positive cancers. IMC-P115C is a half-life extended (HLE) ImmTAC targeting PRAME.
Participants needed: 140
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Immunocore LtdUpdated: Feb 25, 2026Locations: 13
Eligibility criteria
Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 [+5]
Symptomatic or untreated central nervous system metastasis [+9]